Advancements in Pulsed Field Ablation: The VARIPULSE Pro Platform Launch

By HEOR Staff Writer

April 9, 2026

Johnson & Johnson’s launchs the VARIPULSE Pro Platform in Europe. Pulsed field ablation has advanced significantly with the introduction of a new pulse sequence that delivers ablation lesions five times faster than the previous version while maintaining equivalent lesion quality and the established safety profile.

The platform builds on the original VARIPULSE pulsed field ablation system, now approved with CE Mark, and integrates seamlessly with the CARTO 3 mapping system. This combination supports precise lesion delivery and consistent catheter positioning when used with intracardiac echocardiography.

Faster, Cooler, Smarter Pulse Sequence

The core innovation in VARIPULSE Pro is a revised pulse sequence with a lower temperature profile than both the original VARIPULSE sequence and competing pulsed field ablation devices. Preclinical testing confirms it creates equivalent lesions in a fraction of the time, directly improving procedural workflow without compromising precision or safety. Early user feedback from the ongoing VARIPURE study highlights smoother operation and maintained accuracy in lesion sets.

Real-World Evidence Drives European Launch

The introduction of this next-generation platform is supported by robust preclinical data and real-world evidence from the inspIRE trial and other registries. These studies previously demonstrated strong safety outcomes and one-year effectiveness in paroxysmal atrial fibrillation ablation. The VARIPURE multicenter post-market study continues this evidence generation, with twelve-month interim results scheduled for presentation at the European Heart Rhythm Association (EHRA) PFA Summit.

Efficiency Gains with Economic Impact

By dramatically shortening ablation delivery time, VARIPULSE Pro has the potential to reduce overall procedure duration, lower staffing and anesthesia needs, and increase catheter lab throughput. These gains are particularly relevant in European markets where procedural efficiency directly influences cost-effectiveness and hospital resource utilization. As pulsed field ablation matures, health economic analyses will play a key role in quantifying its long-term value in atrial fibrillation management.

Reference url

Recent Posts

Expansion of Community Health Programs by Novartis to Tackle Global Health Disparities

By João L. Carapinha

Novartis’ ambitious scale-up of community health programs aims to close critical gaps in cardiovascular and cancer care. Announced on April 9, 2026, the initiative will expand these community health programs from 11 to more than 30 countries by 2030, including five major U.S. cities, with a stron...
Antimicrobial Resistance Art: Bridging Science and Health Through Visual Storytelling

By João L. Carapinha

Antimicrobial resistance art is powerfully demonstrated in the illustrated album Sketching Antimicrobial Resistance: Thirty Stories, One Health, published in November 2025 by the EU-JAMRAI 2 initiative. The publication brings together 30 original artworks from artists across 30 European ...
Differentiated Visceral Fat Reduction in Early Trials of WVE-007

By João L. Carapinha

April 7, 2026

New clinical evidence shows meaningful visceral fat reduction with a single dose of an investigational therapy. A single 240 mg dose of WVE-007, an investigational INHBE GalNAc-siRNA (SpiNA design), produced continued placebo-adjusted reductions in visceral fat mass (−14.3%; p<0.05) and total ...